Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Lupin-Limited"

270 News Found

Lupin enters China market with approval for Oseltamivir oral suspension
Drug Approval | May 22, 2026

Lupin enters China market with approval for Oseltamivir oral suspension

The approval has been secured in partnership with Yabao Pharmaceuticals, a major player in China’s paediatric medicine segment


Lupin gets tentative FDA nod for Revefenacin inhalation solution
Drug Approval | May 20, 2026

Lupin gets tentative FDA nod for Revefenacin inhalation solution

The drug is indicated for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD)


Lupin debuts in Dow Jones best-in-class indices for ESG performance
News | May 19, 2026

Lupin debuts in Dow Jones best-in-class indices for ESG performance

The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index


Lupin launches Atharv ability neuro-rehabilitation centre in Delhi
News | May 18, 2026

Lupin launches Atharv ability neuro-rehabilitation centre in Delhi

New Delhi facility expands Lupin’s specialized neuro-rehabilitation network after Mumbai and Hyderabad launches


Lupin receives USFDA nod for Famotidine injection
Drug Approval | May 15, 2026

Lupin receives USFDA nod for Famotidine injection

Famotidine Injection USP is a generic version of Pepcid injection to be manufactured at its Nagpur facility for the U.S. market


Lupin Q4 FY26 PBT jumps 115% to Rs 19,280 million
News | May 08, 2026

Lupin Q4 FY26 PBT jumps 115% to Rs 19,280 million

U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit


Lupin receives USFDA approval for generic Ravicti oral liquid
Drug Approval | May 05, 2026

Lupin receives USFDA approval for generic Ravicti oral liquid

Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders


NIFTY Pharma remains resilient amid mixed market sentiment
News | May 05, 2026

NIFTY Pharma remains resilient amid mixed market sentiment

Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures


Lupin launches Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in USA
Drug Approval | April 23, 2026

Lupin launches Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in USA

The product is approved as bioequivalent to Xigduo XR for the indications outlined in the reference drug’s labelling


Lupin subsidiary settles US antitrust case with Humana for $30 Million
News | April 20, 2026

Lupin subsidiary settles US antitrust case with Humana for $30 Million

The litigation involved multiple civil lawsuits alleging anti-competitive practices and violations of federal